Bordetella bronchiseptica is a bacterium that can cause respiratory disease in a variety of animals, including humans. This bacterium produces several toxins, including the Dermonecrotic Toxin, Dermonecrotizing Toxin, and a Putative Toxin.

The Dermonecrotic Toxin is a heat-labile toxin that is known to cause dermal necrosis in experimental animals. This toxin is also involved in the adherence of the bacterium to host cells and the evasion of the host immune system.

The Dermonecrotizing Toxin is a heat-stable toxin that is known to cause dermal necrosis and inflammation in experimental animals. This toxin is thought to contribute to the pathogenesis of respiratory disease caused by Bordetella bronchiseptica.

The Putative Toxin produced by Bordetella bronchiseptica is a toxin whose function is not well understood. However, studies have shown that this toxin is involved in the adherence of the bacterium to host cells and the evasion of the host immune system.

Bordetella bronchiseptica produces several toxins, including the Dermonecrotic Toxin, Dermonecrotizing Toxin, and Putative Toxin, which are involved in the virulence and pathogenesis of the bacterium. These toxins contribute to the adherence of the bacterium to host cells, the evasion of the host immune system, and the development of respiratory disease. Understanding the structure and function of these toxins is important for the development of effective strategies to prevent and treat infections caused by Bordetella bronchiseptica.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, successful recombinant protein expression in heterologous expression systems depends on various factors, including codon preference, RNA secondary structure, and GC content. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins. Compared to pre-optimization, more experimental results demonstrated that the expression level was dramatically increased, ranging from two to a hundred times depending on the gene.

The cDNA and recombinant antigen of Bordetella bronchiseptica can be used to develop rapid diagnostic tests for the detection of the bacteria. These tests can be used to diagnose the infection quickly and accurately, which is important for early treatment and prevention of further complications. The cDNA and recombinant antigen can also be used to produce vaccines that can be used to prevent infection. Vaccines made from Bordetella bronchiseptica cDNA and recombinant antigen can be used to protect both humans and animals from infection.